Protocol
10-216
Full Title
Pilot Study of recMAGE-A3 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Purpose
MAGE cancer-associated proteins are commonly expressed in multiple myeloma cells. The purpose of this study is to evaluate a vaccine that targets the MAGE-A3 protein. The vaccine is designed to train a patient’s own immune system to identify and fight myeloma cells that produce MAGE-A3. It will be used in combination with autologous stem cell transplantation as “consolidation” therapy (which is given after initial “induction” chemotherapy).
Researchers will determine the safety and side effects of MAGE-A3 vaccination, study how patients’ immune systems respond to the vaccine, and see how the vaccine affects multiple myeloma.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have symptomatic multiple myeloma.
- Patients must have had a very good response to their initial (induction) therapy.
- Patients must have MAGE-A3 protein in their myeloma cells.
- Patients must be eligible for an autologous stem cell transplant.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Nikoletta Lendvai at 212-639-3368.
Disease(s)
Hematology: Multiple Myeloma
Locations
Related Diseases
